Treatment of heart failure in African Americans - A call to action

Journal of the National Medical Association

Volumn 103, Issue 2, 2011, Pages 86-98

  Mitchell, Judith E ^a   Ferdinand, Keith C ^b   Watson, Karol E ^c   Wenger, Nanette K ^b   Watkins, Laurence O ^d   Flack, John M ^e   Gavin III, James R ^b   Reed, James W ^f   Saunders, Elijah ^g   Wright Jr , Jackson T ^h  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d Martin Memorial Health Systems   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f MOREHOUSE SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

African americans; Clinical trial; Drugs; Heart; Hypertension; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE PLUS ISOSORBIDE DINITRATE;

AFRICAN AMERICAN; CLINICAL RESEARCH; COMORBIDITY; ETHNICITY; HEART FAILURE; HOSPITALIZATION; HUMAN; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECONDARY ANALYSIS; STANDARD; SURVIVAL;

EID: 79952858299     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30257-1     Document Type: Review

References (89)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
2. Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failure among young adults. N Engl J Med. 2009;360:1179-1190.
3. Yancy CW. Heart failure in African Americans. Am J Cardiol. 2005;96:3i-12i.
4. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298:1525-1532. (Pubitemid 47529386)
5. Mitchell JE, Hellkamp AS, Mark DB, et al. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;155:501-506.
6. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research - Amended, October, 2001. 2001; http://grants.nih.gov/grants/funding/women-min/guidelines-amended-10-2001.htm? print=yes&. Accessed June 22, 2010.
7. Hall WD. Representation of blacks, women, and the very elderly (aged > or = 80) in 28 major randomized clinical trials. Ethn Dis. 1999;9:333-340.
8. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
9. The Black Population: 2000. 2001; www.census.gov/prod/2001pubs/ c2kbr01-5.pdf. Accessed June 22, 2010.
10. Levine RS, Foster JE, Fullilove RE, et al. Black-white inequalities in mortality and life expectancy, 1933-1999: implications for healthy people 2010. Public Health Rep. 2001;116:474-483.
11. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187. (Pubitemid 29449255)
12. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616. (Pubitemid 29093720)
13. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med. 1999;159:505-510. (Pubitemid 29108917)
14. Alexander M, Grumbach K, Remy L, Rowell R, Massie BM. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J. 1999;137:919-927. (Pubitemid 29226303)
15. Vaccarino V, Gahbauer E, Kasl SV, Charpentier PA, Acampora D, Krumholz HM. Differences between African Americans and whites in the outcome of heart failure: Evidence for a greater functional decline in African Americans. Am Heart J. 2002;143:1058-1067.
16. Smedley BD, Stith AY, Nelson AR. Unequal Treatment. Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.
17. Vivo RP, Krim SR, Cevik C, Witteles RM. Heart failure in Hispanics. J Am Coll Cardiol. 2009;53:1167-1175.
18. Deswal A, Petersen NJ, Urbauer DL, Wright SM, Beyth R. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J. 2006;152:348-354. (Pubitemid 44109826)
19. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA. 2003;289:2517-2524. (Pubitemid 37430153)
20. Yancy CW, Strong M. The natural history, epidemiology, and prognosis of heart failure in African Americans. Congest Heart Fail. 2004;10:15-18; quiz 21-12.
21. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511-2517. (Pubitemid 38720549)
22. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135-1142.
23. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97:900-907. (Pubitemid 41552675)
24. Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000;97:3479-3484. (Pubitemid 30183328)
25. Baker DW. Prevention of heart failure. J Card Fail. 2002;8:333-346.
26. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212-216.
27. Fiscella K, Holt K. Racial disparity in hypertension control: tallying the death toll. Ann Fam Med. 2008;6:497-502.
28. Marshall MC, Jr. Diabetes in African Americans. Postgrad Med J. 2005;81:734-740.
29. Smith SC Jr, Clark LT, Cooper RS, et al. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation. 2005;111:e134-139.
30. Andersen NH, Poulsen SH, Poulsen PL, et al. Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clin Sci (Lond). 2006;111:53-59. (Pubitemid 44023411)
31. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)
32. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-194.
33. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.
34. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
35. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10-38.
36. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-533.
37. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178-186. (Pubitemid 43069034)
38. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132-143. (Pubitemid 34114123)
39. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-38. (Pubitemid 34734752)
40. Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail. 2006;12:327-332. (Pubitemid 43817590)
41. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708. (Pubitemid 37000189)
42. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-683. (Pubitemid 46205043)
43. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. (Pubitemid 33126822)
44. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;:314:1547-1552. (Pubitemid 16114684)
45. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992;327:685-691.
46. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
47. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529-1538. (Pubitemid 36543372)
48. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357. (Pubitemid 32378389)
49. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642. (Pubitemid 41124159)
50. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624-1630.
51. Piller LB, Ford CE, Davis BR, et al. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2006;8:649- 656; quiz 657-648.
52. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/ AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
53. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov. 2007;6:127-139.
54. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2010.
55. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838. (Pubitemid 37296092)
56. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
57. Cavallari LH, Groo VL, Momary KM, Fontana D, Viana MA, Vaitkus P. Racial differences in potassium response to spironolactone in heart failure. Congest Heart Fail. 2006;12:200-205.
58. Cavallari LH, Fashingbauer LA, Beitelshees AL, et al. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy. 2004;24:750-756. (Pubitemid 38747860)
59. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
60. Eichhorn EJ, Bristow MR. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med. 2001;2:20-23. (Pubitemid 32223452)
61. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
62. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355. (Pubitemid 26152713)
63. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002;287:883-889. (Pubitemid 34252037)
64. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
65. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with Carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365. (Pubitemid 32378390)
66. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002;105:2429-2434. (Pubitemid 34556397)
67. Taylor MR, Slavov D, Humphrey K, et al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009;19:35-43.
68. Jessup M, Banner N, Brozena S, et al. Optimal pharmacologic and non- pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant. 2006;25:1003-1023. (Pubitemid 44376581)
69. Carmody MS, Anderson JR. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients. Cardiol Rev. 2007;15:46-53. (Pubitemid 46005949)
70. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
71. Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115:1747-1753. (Pubitemid 46648611)
72. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
73. Taylor AL, Lindenfeld J, Ziesche S, et al. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006;48:2263-2267. (Pubitemid 44855413)
74. Bibbins-Domingo K, Fernandez A. BiDil for heart failure in black patients: implications of the US Food and Drug Administration approval. Ann Intern Med. 2007;146:52-56. (Pubitemid 351650320)
75. Cohn JN. The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial. J Law Med Ethics. 2006;34:552-554, 480.
76. Temple R, Stockbridge NL. BiDil for heart failure in black patients: The US Food and Drug Administration perspective. Ann Intern Med. 2007;146:57-62. (Pubitemid 351650321)
77. Kozak LJ, DeFrances CJ, Hall MJ. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2006:1-209.
78. Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49:32-39. (Pubitemid 46026903)
79. McNamara DM, Tam SW, Sabolinski ML, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol. 2006;48:1277-1282. (Pubitemid 44345151)
80. Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005;112:3745-3753. (Pubitemid 43739515)
81. Stiles S. BiDil, regulatory milestone but a tough sell for insurers and patients, charts uncertain course. Heartwire. 2006. www.theheart.org/ article/759547.do. Accessed June 22, 2010.
82. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. (Pubitemid 40110811)
83. Mehra MR, Yancy CW, Albert NM, et al. Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. Heart Rhythm. 2009;6:1727-1734.
84. Farmer SA, Kirkpatrick JN, Heidenreich PA, Curtis JP, Wang Y, Groeneveld PW. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm. 2009;6:325-331.
85. Boyle A. Current status of cardiac transplantation and mechanical circulatory support. Curr Heart Fail Rep. 2009;6:28-33.
86. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report - 2007. J Heart Lung Transplant. 2007;26:769-781. (Pubitemid 47199081)
87. Bello RA, D'Alessandro DA, Frumento RJ, Maybaum S, Goldstein DJ. The role of race in survival after heart transplantation. J Heart Lung Transplant. 2008;27:S113.
88. Srivastava A, Alesh I, Williams C, et al. Comparison of post cardiac transplant outcomes between African American (AA) and Causasian (C) patients: A single center experience. J Heart Lung Transplant. 2008;27:S112-S113.
89. Powell LH, Calvin JE Jr, Mendes de Leon CF, et al. The Heart Failure Adherence and Retention Trial (HART): design and rationale. Am Heart J. 2008;156:452-460.